Cingulate Inc. has announced the closing of a $12 million private placement, with shares priced at $5.04 each and 80% warrant coverage. The financing, which included participation from Falcon Creek Capital and insiders, is subject to a 180-day investor lock-up and will support operations and the potential commercial launch of CTx-1301, pending FDA approval. The securities were issued in an unregistered sale and are subject to a future resale registration statement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cingulate Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9655578-en) on February 17, 2026, and is solely responsible for the information contained therein.
Comments